comparemela.com

Latest Breaking News On - Magendie neurocenter - Page 3 : comparemela.com

Aelis Farma Announces Positive Results From Its Safety Trials in Healthy Volunteers and the Authorization to Start the First Trial in People with Down Syndrome with AEF0217, its Drug Candidate for the Treatment of Cognitive Disorders

AEF0217 is being developed as the first treatment for cognitive deficits caused by a hyperactivity of the CB1 receptor, the first indication being those linked to Down syndrome (Trisomy 21), which

France generalUnited statesArthur rouillDusan oresansky hugo willefertVincenzo piazzaDaelis farmaMagendie neurocenterTorre fornellInserm transfert initiativeNeurology of the french academy sciencesEuropean commissionHospital del mar medical research instituteSignaling specificRafael de la torre fornellPier vincenzo piazzaInserm grand prix

Aelis Farma CEO Pier Vincenzo Piazza Receives the EY Entrepreneur of the Year Award

Pier Vincenzo Piazza has won in the "Scale-Up" category for France's Nouvelle Aquitaine region Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS, PEA-PME eligible), a clinical-stage

United statesUnited kingdomHaute normandieArthur rouillDusan oresansky hugo willefertVincenzo piazzaDaelis farmaMagendie neurocenterInserm magendie neurocenterInserm transfert initiativeNeurology of the french academy sciencesErnst young globalErnst young global limitedPier vincenzo piazzaNouvelle aquitaineNord de france

Aelis Farma: Availability of the 2022 Half-year Financial Report

Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today

United statesArthur rouillDusan oresansky hugo willefertVincenzo piazzaDaelis farmaMagendie neurocenterInserm magendie neurocenterInserm transfert initiativeFrench financial markets authority autoritNeurology of the french academy sciencesRegulatory newsFrench financial markets authoritySignaling specificPier vincenzo piazzaInserm grand prixGrand prix

Aelis Farma reports 2022 half-year financial results and confirms its development objectives

H1 2022 marked by the start of recruitment for the phase 2b study with AEF0117 for the treatment of cannabis addiction Solid cash position at €39.8 million as of June 30, 2022, including the

United statesLong beachArthur rouillDusan oresansky hugo willefertVincenzo piazzaDaelis farmaFrances levinInserm magendie neurocenterMagendie neurocenterInserm transfert initiativeResearch tax creditNeurology of the french academy sciencesResearch societyColumbia universityDown syndromeEuronext paris

Aelis Farma Will Participate in the Addiction 2022 Conference Dedicated to Innovation in the Treatment of Addictions

Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today

United statesArthur rouillDusan oresansky hugo willefertVincenzo piazzaDaelis farmaMagendie neurocenterInserm magendie neurocenterInserm transfert initiativeNeurology of the french academy sciencesRegulatory newsPier vincenzoSignaling specificPier vincenzo piazzaInserm grand prixGrand prixFrench academy

vimarsana © 2020. All Rights Reserved.